Aligos: Phase 2 HBV interim – DSMB ups HBeAg- sample size to 100; FDA Fast Track granted

Aligos Therapeutics, Inc.

DSMB recommended increasing HBeAg- cohort from 74 to 100 participants to optimize power; futility criteria not met.
Study drugs well-tolerated; no viral breakthrough; safety data reviewed across all 174 enrolled participants.
FDA granted Fast Track Designation for pevifoscorvir sodium based on 96-week Phase 1 data.
Topline data from B-SUPREME study remains on track for 2027; enrollment in HBeAg- cohort expected by H2 2026.
Aligos remains blinded to participant-level data; 103 enrolled in HBeAg+ cohort (Part 1a).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.